CCO Treatment Updates
Advances in Metastatic Colorectal Cancer: Molecular Pathways, Biomarkers, and Clinical Results
Virtual Presentations
Update on the Science of Current Therapy for Metastatic Colorectal Cancer
|
Program Director: J. Randolph Hecht, MD
|
|
J. Randolph Hecht, MD, reviews current therapeutic options for metastatic colorectal cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the science behind the current standard of care for metastatic colorectal cancer
- Recall the signaling pathways and mechanisms of action for vascular endothelial growth factor and endothelial growth factor receptor in colorectal cancer
- Discuss vascular endothelial growth factor– and endothelial growth factor receptor–targeted strategies in the treatment of colorectal cancer
|
Update on the Science of Current Therapy for Metastatic Colorectal Cancer
 |
|
Download slides reviewing the science behind current therapies for metastatic colorectal cancer
Format: Microsoft PowerPoint (.ppt) |
File size: 963 KB
|
Controversies in Care: Using Clinical Data to Guide Treatment Selection
|
Program Director: J. Randolph Hecht, MD
|
|
Cathy Eng, MD, reviews recent data regarding the use of clinical data to optimize treatment of colorectal cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe studies evaluating the use of sequential vs combination chemotherapies in the treatment of colorectal cancer.
- Summarize data regarding the use of maintenance therapy and chemotherapy-free intervals in the treatment of metastatic colorectal cancer.
- Describe recent clinical trial data regarding the addition of biologic therapies to chemotherapy regimens for patients with colorectal cancer.
|
Controversies in Care: Using Clinical Data to Guide Treatment Selection
 |
|
Download slides providing answers to some of the grey areas in metastatic colorectal cancer management.
Format: Microsoft PowerPoint (.ppt) |
File size: 1.33 MB
|
Exploring Biomarkers and Surrogates in Optimizing Patient Outcomes
|
Program Director: J. Randolph Hecht, MD
|
|
Eric Van Cutsem, MD, PhD, discusses the emerging use of biomarkers in the clinical management of patients with metastatic colorectal cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the prognostic relevance of skin rash in patients with metastatic colorectal cancer receiving treatment with epidermal growth factor receptor inhibitors
- Explain the use of EGFR and KRAS status as biomarkers in the setting of colorectal cancer
- Review recent clinical trial data regarding EGFR inhibitors vs best supportive care for patients with metastatic colorectal cancer
|
Exploring Biomarkers and Surrogates in Optimizing Patient Outcomes
 |
|
Download slides reviewing data on new biomarkers for optimizing treatment in metastatic colorectal cancer.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.43 MB
|
Potentially Curable Metastatic Disease in Colorectal Cancer: Neoadjuvant Approach to Liver-Limited Disease
|
Program Director: J. Randolph Hecht, MD
|
|
Edward Chu, MD, reviews neoadjuvant strategies to improve outcomes in patients with liver-limited metastatic colorectal cancer.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Summarize current typical survival outcomes following hepatic resection
- Discuss criteria defining resectability in patients with metastatic colorectal cancer
- Describe outcomes with various neoadjuvant chemotherapy regimens used in the perioperative treatment of patients with metastatic colorectal cancer
- Review recent clinical trial data regarding the addition of targeted biologic agents to neoadjuvant chemotherapy regimens used in the treatment of metastatic colorectal cancer
|
Potentially Curable Metastatic Disease in Colorectal Cancer: Neoadjuvant Approach to Liver-Limited Disease
 |
|
Download slides reviewing neoadjuvant approaches to metastatic colorectal cancer.
Format: Microsoft PowerPoint (.ppt) |
File size: 638 KB
|
Disclaimer: The materials published on the Clinical Care Options
Web site reflect the views of the reviewers or authors of the
CCO
material, not those of Clinical Care Options, LLC, the CME provider,
or the companies providing educational grants. The materials may
discuss uses and dosages for therapeutic products that have not been
approved by the United States Food and Drug Administration. A qualified
healthcare professional should be consulted before using any therapeutic
product discussed. Readers should verify all information and data before
treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|
|